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1. Introduction  
The term 'Inflammatory Bowel Disease' (IBD) refers to conditions characterized by chronic 
inflammation of the gastrointestinal tract, including ulcerative colitis (UC) and Crohn's 
disease (CD). UC and CD have distinct pathologic features, for example the location, 
depth and severity of inflammation. For UC, inflammation is confined to the colon and 
rectum, is continuous, and is superficial, affecting only the mucosal layer of the intestinal 
wall. In contrast, the inflammation seen in CD can affect any part of the gastrointestinal 
tract from mouth to anus, is typically discontinuous or ‘patchy’, and involves all layers  
of the intestinal wall (Abraham and Cho, 2009). In spite of these differences, there is  
also overlapping pathology, suggesting some common causal factors and potential 
treatments. 
The exact cause of IBD is still unclear, although it appears to involve a complex interaction 
between genetic susceptibility and environmental triggers including the resident microbial 
population of the intestinal tract (Abraham and Cho, 2009). The gastrointestinal tract uses a 
system of tolerance and controlled inflammation to limit the response to dietary or 
bacterially-derived antigens in the intestinal tract. When this complex system breaks down, 
either by a chemical or pathogenic insult in a genetically predisposed individual, the 
resulting innate immune response may lead to IBD. Although the aetiopathogenesis of IBD 
remains unsolved, current evidence indicates that increased activation of T cells, and an 
imbalance of Treg and Th1, Th2 and Th17 cells play important roles (Sanchez-Munoz et al., 
2008). Activation of macrophages also seems to be important, with increased production of 
the macrophage-derived cytokines such as TNF-alpha, IL-1 and IL-6 contributing to the 
observed inflammation. The triggering factor(s) are still to be elucidated, although host 
response to microbial pathogens includes self-defense mechanisms including defensins, 
pattern recognition receptors and Toll-like receptors; this suggests there may be an element 
of “self” recognition triggering the immune response (Strober et al., 2002). 
Neuroimmunomodulation in IBD is another interesting possible mechanism with its 
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implications relating to the influence of the brain-gut axis on the perpetuation of intestinal 
inflammation (Tsianos and Katsanos, 2009).  
Evidence for a genetic component comes from various sources such as twin studies and 
familial aggregation, which suggest that CD has a stronger genetic component than UC 
(Halfvarson et al., 2003). A number of genome-wide association studies (GWAS) have also 
identified several key gene variants which occur at a higher rate in people with IBD compared 
with controls who do not have any gastrointestinal symptoms (Barrett et al., 2008). These 
findings have led to significant recent progress in the understanding of the genetic component 
of IBD. Relevant genes and pathways have been well characterized for CD, such as innate 
immunity, adaptive immunity, and more recently autophagy (Massey and Parkes, 2007; Van 
Limbergen et al., 2009). The part played by autophagy had not been recognized prior to the 
comprehensive GWAS data, but these data have allowed research to focus on this pathway 
with a resultant significant increase in understanding of how it may contribute to IBD 
pathogenesis (Brest et al., 2010). There is also overlap with other diseases, particularly auto-
immune diseases, showing genetic variants in the same pathways (Lees et al., 2011). 
The genetic component of UC is less well understood than CD, but it seems likely that 
variants in mucosal barrier function genes (ECM1, CDH1, HNF4ǂ, and laminin B1) are 
associated with increased risk of UC, and impaired IL10 signalling appears to be a key 
pathway in intestinal inflammation (Thompson and Lees, 2011). It has been observed that 
there are currently ninety nine published IBD susceptibility loci (Lees et al., 2011), and genetic 
variants contributing to both CD and UC have recently been reviewed (Paul et al., 2011). 
Recent advances in understanding the genetic contribution to IBD have served to highlight 
the genetic complexity of the disease, as reflected by the large number of genes potentially 
implicated in disease pathogenesis or risk. The analysis becomes more complex as risk genes 
for one ethnic group may not be replicated in another. This has been shown several times, 
with gene variants identified in populations of European origin showing only limited 
agreement in, for example, North Indian (Juyal et al., 2011), Indian (Mahurkar et al., 2010), 
and Japanese (Nakagome et al., 2010) population groups. A combination of the genetic and 
pathological complexity has contributed to the relatively poor understanding of IBD. The 
widely varying phenotype suggests many different pathways for the disease, but attempts 
to sub-classify CD and UC in clinical terms have only been partially successful. This lack of 
clarity in clinical classification has hampered attempts at genotype-phenotype associations, 
which has in turn contributed to difficulties in establishing appropriate clinical interventions. 
Recent studies have highlighted the relationship between disease and the intestinal 
microbiota, with the suggestion that an inappropriate immune/inflammatory response to 
normal intestinal bacteria may be a key triggering factor (Nell et al., 2010). Environment 
may also play an important role, with diet in particular having an influence, if not in the 
initiation of the disease, then certainly in the maintenance and/or amelioration of disease 
symptoms. As part of a long-term research project (Nutrigenomics New Zealand (NuNZ); 
www.nutrigenomics.org.nz) we have identified a number of foods which are perceived by 
people with IBD as being either detrimental or beneficial in terms of managing the symptoms 
of both CD and UC (Petermann et al., 2009b) or show evidence of ameliorating intestinal 
inflammation in animal studies (Knoch et al., 2009; Nones et al., 2009; Knoch et al., 2010). 
There is a very real importance in seeking answers to the effective treatment of IBD because 
it is such a debilitating condition, and its prevalence is increasing (Cosnes et al., 2011). There 
is reduced quality of life from continuing disease activity and significant long-term 
complications that develop with persistent intestinal inflammation. There is clearly an as-yet 
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unmet clinical need due to limitations of current treatments. These tend to rely on the use of 
non-specific anti-inflammatory agents (such as 5-aminosalicytic acid and corticosteroids) 
and immunosuppressive drugs that may cause severe side effects, and in a significant 
percentage of the patients do not provide appreciable benefits (Grimm, 2009). Other 
approaches such as targeted interruption of the inflammatory cascade using anti-TNF 
monoclonal antibodies have been very successful, but greater understanding of the 
inflammatory process is required to identify other pivotal points in the relevant pathways 
that may be blocked by similar monoclonal antibodies. Surgical removal of diseased 
portions of the gastro-intestinal tract can be effective but highlights the failure of medical 
treatment to prevent the long-term consequences of chronic inflammation. 
IBD may represent a heterogenic group of diseases that share similar pathologies and 
mechanisms of tissue damage, but are initiated by different events and characterized by a 
variety of immune abnormalities (Tsianos and Katsanos, 2009). A variety of mouse models 
of IBD have been used. This chapter will discuss if this represents the complexity and 
heterogeneity of IBD or if the multiple models simply reflect the failure of any one model to 
truly recreate the human disease. Research using these models has attempted to better 
understand disease pathogenesis and treatment, and to investigate the complex interactions 
that may be contributing to the pathogenesis. A better understanding of all these factors will 
provide new insights into the mechanisms by which intestinal inflammation is 
inappropriately triggered, and provide new targets for medical therapies.  
In this chapter, we will review some of the key animal models used in IBD research, 
consider some of the findings from this research, and finally and most importantly discuss 
whether these research findings are being applied in a clinical setting to make a real impact 
for people with IBD.  
2. Animal models of IBD 
Animal models of IBD have been used for over fifty years. Early models resulted from the 
observation that a variety of laboratory animals fed extracts from certain species of seaweed 
displayed similar symptoms to human IBD (Marcus and Watt, 1969). Subsequent refinement 
and development of this model led to a variety of chemically-induced models. More 
recently, gene variants relevant to IBD have been incorporated into animal models 
(primarily mice and rats) and these have been used extensively (Jurjus et al., 2004). These 
models have recently been comprehensively reviewed in the context of the role of intestinal 
bacteria in the development of IBD (Nell et al., 2010). 
Clinical features in animal models that are of relevance to human IBD include weight loss, 
anaemia, diarrhoea, visible or occult blood, and sometimes mucus in the faeces. 
Pathologically there are similarities such as ulceration of variable extent and largely 
confined to the mucosa, some loss of haustration (i.e., disappearance of the horizontal folds 
of the colon), granularity of the mucosa along with pseudo-polyps and polypoidal 
formations (UC features), as well as strictures leading to intestinal obstruction (a feature of 
CD). Histological features in common are acute, subacute, and chronic inflammatory 
changes in the mucosa, with occasional crypt abscesses and cystic dilatation or distortion of 
mucosal glands, mucosal ulceration in various stages of progression and healing, and 
hyperplastic changes of the glandular epithelium.  
Animal models of IBD have significant advantages – one can investigate not only factors 
concerned in pathogenesis, but also the secondary effects of ulceration, e.g., liver changes, 
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effects on protein metabolism, electrolytic changes in the cellular and extracellular spaces, 
and other systemic complications. They may also be used to study the influence of drugs or 
other potential therapies on the pathogenesis and course of the disease process. However, 
none of the current IBD models in itself constitutes a faithful equivalent for the human 
diseases (this will be discussed in more detail in the final section of this chapter). It may 
therefore be essential to evaluate the effect of any candidate therapies in several IBD models. 
The wide variety of models of IBD includes chemically-induced models, adoptive transfer 
models, and genetically modified models such as gene knockouts and transgenic animals. 
We will consider each of these types of model as they apply to IBD, focusing in particular on 
those models with a genetic basis, describing some of our work using the Il10–/–and Mdr1a 
models and, more recently, the Nod22939iC model. 
2.1 Chemically induced models of IBD 
A variety of agents have been used as inducers of colitis in animal models, including 
carragenin (Moyana and Lalonde, 1990), acetic acid (MacPherson and Pfeiffer, 1978), and 
very recently, sodium hydroxide (Kocak et al., 2011). While predominantly used in rodents, 
compounds such as these have also been used to develop colitis models in dogs (Shibata et 
al., 1993) and rabbits (Depoortere et al., 2004). The two most widely used chemicals used to 
induce IBD in such models are 2,4,6-trinitrobenzene sulfonic acid (TNBS) and dextran 
sodium sulphate (DSS). Both act via acute destruction of the intestinal barrier, although 
TNBS more closely mimics CD, and DSS UC (Alex et al., 2009). We will consider these two 
compounds in greater depth as examples of chemically-induced models of colitis. 
2.1.1 DSS 
DSS, (C6H7Na3O14S3)n, is a polyanionic derivative of dextran, and is used for such diverse 
applications as selective precipitation of lipoproteins (Burstein et al., 1970), acceleration of 
probe hybridization to membrane-immobilized DNA (Wahl et al., 1979), and the release of 
DNA from DNA-histone complexes (Kent et al., 1958). Its use in animal models is more 
recent, and it has been widely used in both mice and rats in the context of colorectal cancer 
(Ishioka et al., 1987) in addition to its role as a model of intestinal colitis (Okayasu et al., 
1990) which we are considering here. 
DSS is most commonly administered in the drinking water, often as a 3% solution 
(Johansson et al., 2010), although it can also be administered rectally. This compound results 
in inflammation in wild-type animals that starts distally after about five days and is 
confined to the colonic mucosa (Fig.1, [A–C]). How DSS initiates the colonic inflammation is 
not well understood despite its wide use, although a recent study investigating DSS both in 
vitro (effect on the inner mucus layer secreted by mucosal explants) and in vivo (mice given a 
3% DSS solution) showed that DSS has a direct effect on the inner mucus layer, allowing 
bacteria to penetrate this layer before any signs of inflammation could be observed. The 
authors concluded that a lack of the inner colon mucus layer may be an initial event in the 
development which allows bacteria to reach the epithelial cells and thus trigger the 
characteristic inflammatory reaction (Johansson et al., 2010).  
As well as being used in wild-type mice, DSS is also used in some genetic models of IBD, 
which while being genetically predisposed to inflammation still require this challenge in 
order to trigger an inflammatory response. This is the case for the Nod22939iC mouse model 
(described in more detail in section 2.3.3) in which DSS treatment led to more severe colonic 
inflammation and ulceration than wild-type mice (Maeda et al., 2005). 
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2.1.2 TNBS 
TNBS is a nitroaryl oxidizing acid with extreme oxidising properties. TNBS dissolved in 
ethanol induces severe colonic damage, which is characterized by areas of necrosis 
surrounded by areas of acute inflammation. The damage is associated with high 
myeloperoxidase activity, mainly as a reflection of neutrophilic infiltration into the damaged 
tissue (Veljaca et al., 1995) and caustic injury to the colonic epithelium and interstitium as 
measured by the rapid and dramatic increases in mucosal permeability (Yamada et al., 
1992). It has been assumed that interstitial TNBS initiates the inflammatory response via 
macrophage-mediated recognition and degradation of TNBS-modified mucosal cells and 
proteins (Grisham et al., 1991). TNBS may reduce mucosal hydrophobicity by reacting with 
the surface-active phospholipids of the colonic mucosa. Reduced hydrophobic integrity of 
the colonic mucosa may contribute to TNBS-induced colonic inflammation (Tatsumi and 
Lichtenberger, 1996). TNBS causes necrosis and deeper tissue damage (somewhat akin to 
transmural inflammation seen in CD). 
2.2 Adoptive transfer models 
The adoptive transfer model involves transferring T cells or immune tissue from one mouse 
into a histocompatible, adoptive host which results in colitis. A variety of donors and hosts 
have been used, including CD4+ T cells transferred into severely immunodeficient (SCID) 
mice (Rudolphi et al., 1996), hsp60-specific CD8 + T-lymphocytes into TCR–/– or SCID mice 
(Steinhoff et al., 1999) and CD4+CD25- T cells into SCID mice (Kjellev et al., 2006).  
Adoptive transfer models represent well-characterized models of chronic colitis induced by 
disruption of T cell homeostasis. The colitis is characterised by transmural inflammation, 
epithelial cell hyperplasia, polymorphonuclear leukocyte (PMN) and mononuclear 
leukocyte infiltration, crypt abscesses, and epithelial cell erosions. The disease model is 
responsive to a variety of treatment protocols (Ostanin et al., 2009). The adoptive host can 
influence the severity and location of colitis, with the recombinase activating gene-1-
deficient (RAG−/−) deficient mouse showing both small bowel inflammation and colitis, and 
therefore being the model most relevant for CD (Ostanin et al., 2009).  
Because these models rely on the transfer of T cells, they are particularly useful in 
understanding how different T cell populations might contribute to the pathogenesis of IBD. 
2.3 Genetic models of IBD 
Recent research using novel genetic technologies has resulted in the identification of a large 
number of genes, variants of which may be related to increased susceptibility to IBD. Tools 
such as GWAS have identified susceptibility genes such as those encoding the autophagy 
protein ATG16L1, the receptor for prostaglandin E2 (CD), and the intestinal barrier protein 
ECM1 (UC) (Paul et al., 2011). Existing mouse and rat models containing relevant genetic 
variants, or those incorporating these newly identified variants, have been used to further 
investigate the genetic contribution to IBD. Gene variant models include knockouts 
(interleukin-2 KO/IL-2 receptor (R)ǂ KO mice, T cell receptor (TCR) mutant mice, TNF-3’ 
untranslated region (UTR) KO mice, interleukin-22 KO mice) and transgenic models (IL-7 
transgenic mice, signal transducer and activating transcription (STAT)-4 transgenic mice, 
HLA B27 transgenic rats), and have been comprehensively reviewed elsewhere (Jurjus et 
al., 2004; Mizoguchi and Mizoguchi, 2010). Some of these models develop spontaneous 
colitis as a result of the genetic variant, others can require additional intervention to act as 
a trigger for the onset of inflammation (Mizoguchi and Mizoguchi, 2010). For the 
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purposes of this chapter, we will consider three models with which we have some 
experience; the interleukin 10 gene-deficient, multi-drug resistant gene-deficient, and 
Nod22939iC mouse models.   
2.3.1 The interleukin 10 gene-deficient (Il10–/–) mouse model 
The Il10–/– mouse model has been widely used as a model of IBD (Kuhn et al., 1993; Berg, D. 
J. et al., 1996; Barnett et al., 2010). This mouse model lacks a functional version of the 
important anti-inflammatory cytokine interleukin 10. When originally developed, these 
mice were observed to be anaemic and underweight, and showed a chronic enterocolitis 
involving the entire intestinal tract. The intestinal pathology (Fig.1 [D–E]) was characterized 
by variable mucosal inflammation, abnormal crypt and villus structures, inflammatory cell 
infiltration and epithelial destruction (Kuhn et al., 1993). 
The precise mechanism that results in inflammation in Il10–/– mice is unclear although, as is 
the case in human IBD, there is evidence of an inappropriate inflammatory response to 
normal intestinal flora (Sydora et al., 2003). This was seen in studies where mice raised in 
germ-free conditions showed no colitis (Sellon et al., 1998), while those under specific-
pathogen free conditions showed a local colitis, and not the general enterocolitis seen in 
animals raised under conventional conditions (Kuhn et al., 1993). More specific studies of 
bacterial interactions have shown that clinical isolates of Enterococcus faecalis induce IBD-like 
symptoms in germ-free Il10–/– mice (Balish and Warner, 2002; Kim et al., 2005). Enterococcus 
species are a common component of the intestinal flora of healthy humans and animals (Jett 
et al., 1994), with E. faecalis and E. faecium being the most commonly detected species in the 
human bowel (Noble, 1978; Tannock and Cook, 2002). Both carry a variety of virulence 
factors which may play a role in the establishment of inflammation (Jett et al., 1994). 
We have utilized Il10–/– mice inoculated with normal intestinal bacteria, including 
Enterococcus species (Barnett et al., 2010), to investigate the role of diet in intestinal 
inflammation. We have shown that food components such as polyunsaturated fatty acids 
(Knoch et al., 2009; Knoch et al., 2010) can prevent or ameliorate the level of intestinal 
inflammation, and have characterized changes in gene expression in association with this 
change in inflammation to better understand the mechanisms through which such food 
components might be acting.  
We have also used metabolomic analysis to measure urinary metabolite differences between 
Il10–/– and wildtype C57BL/6 mice, and to determine which of these differences were 
associated with intestinal inflammation (Lin et al., 2010). Eleven metabolites, including 
glutaric acid, 2-hydroxyglutaric acid and 2-hydroxyadipic acid, were significantly different 
in Il10–/– compared with C57 mice, but these differences were not related to the severity of 
inflammation, and were possibly associated with the genetic manipulation that produced 
these animals, rather than any inflammatory-related function of IL-10. In contrast, fucose, 
xanthurenic acid and 5-aminovaleric acid were among fifteen metabolite differences 
associated with intestinal inflammation (Lin et al., 2010). The presence of defined 
metabolites associated with inflammation may be of benefit in enabling a non-invasive 
measurement of the severity of inflammation in human IBD. 
2.3.2 The multi-drug resistant (Mdr1a) mouse model 
Mdr1a (otherwise known as ATP-binding cassette, sub-family B (MDR/TAP), member 1A 
(Abcb1a)), is a member of a family of proteins that actively transport a wide range of  
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Fig. 1. Comparison of microscopic features of colon inflammation in a variety of animal 
models. DSS rat: Panels [A] to [C]. An untreated rat in panel [A] exhibits normal crypt 
distribution, high numbers of goblet cells, and intact surface enterocytes. There are 
noinflammatory aggregates, and immune cells present are well within normal limits. Sub 
mucosa and muscularis region are of normal size and proportion to the mucosa region. In a 
moderately inflamed colon [B], crypt loss, crypt shortening and aberrant crypts can be seen 
along with the associated loss of goblet cells, and some loss of integrity of the surface 
A B C 
D E 
F G 
www.intechopen.com
 Ulcerative Colitis – Treatments, Special Populations and the Future 
 
168 
enterocyte layer. An increasing number of inflammatory cells in the mucosa and submucosa 
region can also be seen. In a severely inflamed colon [C], the surface enterocyte layer is 
severely impaired. There is loss of crypts, and the majority of those still present are aberrant in 
structure, showing severe shortening. The number of goblet cells visible is significantly 
reduced and infiltrating inflammatory cells are evident throughout all definable regions of the 
tissue. Thickening/swelling/oedema of the submucosa region can also be observed. 
Panel [D] shows a control C57 mouse which exhibits the intact enterocyte layer, abundant 
goblet cells, and normal crypt definition of a healthy mouse colon. In contract, the Il10–/– 
mouse in panel [E] shows aberrant crypts (black arrow) and crypt hyperplasia (swelling), an 
increase in inflammatory cells in the lamina propria and the presence of RBCs in the mucosa 
region of the tissue. There is also a decrease in goblet cell number and loss of surface 
enterocyte integrity. In panel [F], the FVB/N mouse is generally normal, although there is 
a lymphoid aggregate (arrow). In contrast, the Mdr1a mouse colon [G] shows significant 
inflammatory cell infiltration, aberrant crypts and some loss of surface enterocyte 
integrity 
structurally unrelated, amphiphilic hydrophobic drugs from the cell, many of which are 
toxic compounds (Panwala et al., 1998). There is evidence that single nucleotide 
polymorphisms (SNPs) of the MDR1 gene in the human population are associated with 
changes in the risk of UC (Huebner et al., 2009). Mice with a homozygous disruption of the 
mdrla gene were originally developed to better understand the physiological significance 
and other possible biological roles of this protein (Panwala et al., 1998). It was subsequently 
shown that these mice spontaneously develop intestinal inflammation (Fig.1, [F–G]) similar 
to that seen in human IBD, with infiltration of intestinal cells into the lamina propria, 
increased crypt length, goblet cell loss, interstitial oedema, ulceration (ranging from 
superficial to transmural) and crypt abscesses (Banner et al., 2004). These mice have since 
been used as an experimental model of colitis in a number of studies. 
As in the case of the Il10–/– mice, we have used the Mdr1a mouse model to investigate 
potential beneficial effects of food components on intestinal inflammation (Nones et al., 
2009). These studies have shown that the polyphenolic compound curcumin, but not rutin, 
significantly reduced colonic inflammation in Mdr1a mice. Microarray analyses suggested 
that curcumin reduced colon inflammation by up-regulating xenobiotic metabolism and 
down-regulating pro-inflammatory pathways, possibly through the pregnane X or retinoid 
X receptors (Nones et al., 2009). 
2.3.3 The Nod22939iC mouse model 
The NOD2 protein is important in the discrimination between normal intestinal flora and 
pathogenic bacteria (Inohara et al., 2002). It belongs to a class of pattern recognition 
receptors of the innate immune system that recognise evolutionarily conserved pathogen-
associated molecular patterns. Pattern recognition by NOD2 initiates the signal transduction 
that leads to translocation of nuclear factor-kappa B (NF-κB) to the nucleus, transcription of 
specific genes and eventual activation of appropriate innate and adaptive immune 
responses (Inohara et al., 2002). 
In humans, the most common CD susceptibility allele is 3020insC, which encodes a 
truncated NOD2 protein lacking the last 33 amino acids (Ogura et al., 2001). It has been 
established that this SNP, and possibly others in the NOD2 gene, are important genetic 
determinants of CD risk in the NZ population (Leung et al., 2005). Variants of the NOD2 
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gene have also been shown to interact with other genes influencing bacterial recognition 
which results in an increased risk of IBD (Petermann et al., 2009a). 
A mouse model has been generated containing a susceptibility allele homologous to that in 
humans (Maeda et al., 2005). These mice (Nod22939iC) express a protein truncated by 33 amino 
acids, which by itself does not alter the phenotype: homozygous Nod22939iC mice were healthy, 
not showing abnormalities of the gastrointestinal tract or other organs (Maeda et al., 2005). 
However, when 8-12 week old mice were exposed to DSS treatment (3% in drinking water), 
they exhibited increased body weight loss, increased colonic inflammation and ulceration and 
more apoptotic cells in the lamina propria when compared to similarly treated wild-type mice. 
The intestinal inflammatory response to DSS was dramatically reduced by oral antibiotics, 
suggesting that enteric bacteria elicit the inflammatory response to DSS, and without bacterial 
exposure, Nod22939iC mice have the same reaction as WT counterparts (Maeda et al., 2005).  
We have inoculated these mice with intestinal bacteria, including Enterococcus strains, using 
the same protocol as previously applied to Il10–/– mice (Barnett et al., 2010). While there was 
some evidence of reduced body weight associated with the Nod22939iC mutation (WT > 
Nod22939iC heterozygotes > Nod22939iC homozygotes), there was no data to suggest an effect of 
either genotype or bacterial inoculation on intestinal phenotype, as assessed by assigning a 
histological injury score (Barnett et al, “unpublished observations”). It therefore seems likely 
that disruption of the epithelial barrier, for example with DSS, is necessary to enable 
bacterial infiltration which leads to altered NF-kB activation and IL-1ǃ secretion in the 
Nod22939iC mice (Maeda et al., 2005). 
This preliminary evidence suggests that the Nod22939iC mutation is not, of itself, sufficient to 
lead to increased intestinal inflammation, requiring a simultaneous disruption of the 
epithelium. This is an example of an interaction between an environmental trigger, genetic 
susceptibility and inappropriate response to normal bacteria leading to intestinal 
inflammation. This model may therefore be particularly relevant for individuals in the 
human population carrying the homologous gene variant, and metabolomics approaches 
applied to this model may enable, for example, early detection of susceptibility to IBD and 
therefore earlier and more effective responses. 
3. Lessons learned from mouse models 
The body of evidence using mouse models of IBD is large, and there is no doubt that much 
has been learned by using such models. A selection of some key observations is shown in 
Table 1. This is clearly not an exhaustive list, but it serves to demonstrate some of the 
important areas in which animal models have contributed. In addition to more precisely 
defining the pathogenesis of IBD, insights have been gained into the inflammatory process 
itself, and this is relevant both in terms of colitis per se as well as being useful for the 
complications or systemic effects that may arise from a prolonged period of inflammation 
occurring within the intestine. There has also been progress in understanding the complex 
interactions occurring within the intestinal tract between the resident microbial population 
and the host.  
Models such as the Il10–/– and adoptive transfer models have been particularly helpful in 
terms of generating deeper understanding of the inflammatory process itself. This has 
included better defining some of the leukoctye-epithelial cell interactions and the 
importance of cell adhesion, as well as the roles of the Th1 response in CD and the Th2 
response (albeit an atypical one) in UC (Strober et al., 2002). 
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Model Observation Reference 
TNBS 
Fatty acid amide hydrolase (FAAH) inhibitors 
are promising targets for IBD treatment. 
(Andrzejak et al., 2011) 
DSS 
DSS makes the inner colon mucus layer 
permeable to bacteria, which reach the 
epithelial cells and trigger an inflammatory 
reaction. Altered inner colon mucus layer may 
be an early event in colitis development. 
(Johansson et al., 2010) 
Various 
IBD is much more complicated than currently 
predicted. Cell-specific, tissue-specific, or 
personalized approaches may be required for 
effective IBD therapy. 
(Mizoguchi and 
Mizoguchi, 2010) 
Various 
A significant (as-yet not precisely defined) role 
for IL-10 in orchestrating intestinal immune 
homeostasis. 
(Paul et al., 2011) 
SAMP1/Yit 
A hypothesis that CD is caused by a 
dysregulated immune response to an unknown 
(bacterial?) antigen in a genetically susceptible 
host. 
(Pizarro et al., 2011) 
TNFΔARE 
Deregulation of TNF gene leads to spontaneous 
development of  chronic ileitis similar to that of 
CD. 
(Pizarro et al., 2011) 
Various 
Response in IBD takes the form of either a Th1 
or Th2 T cell-mediated inflammation driven by 
antigens associated with normal mucosal 
microflora ("self" antigens). 
(Strober et al., 2002) 
Il10–/– 
Importance of Enterococcus bacterial strains in 
development of intestinal inflammation. 
(Balish and Warner, 
2002; Barnett et al., 
2010) 
Il10–/– 
Omega-3 and -6 polyunsatured fatty acids 
reduce intestinal inflammation in the Il10–/– 
mouse, in the case of n-3 via peroxisome 
proliferator-activated receptor a. 
(Knoch et al., 2009; 
Knoch et al., 2010) 
CD4+ SCID 
mice 
Flagellins act as antigens that stimulate 
pathogenic intestinal immune reactions. 
(Lodes et al., 2004) 
Mdr1a 
Reduction of inflammation associated with 
diets enriched with polyphenolic compounds. 
(Nones et al., 2009) 
Table 1. Some key observations from studies using mouse models of IBD 
A variety of models have contributed to progress in understanding the complex interactions 
occurring within the intestinal tract between the resident microbial population and the host. 
A number of studies using Il10–/– mice have highlighted the importance of specific intestinal 
bacteria such as Enterococcus strains in triggering inflammation (Balish and Warner, 2002; 
Barnett et al., 2010). In terms of relevant components of bacteria which may be important, 
flagellins are molecules of the bacterial flagellum which are known to activate innate 
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immunity via toll-like receptor 5 (TLR5), and act as critical targets of the host’s acquired 
immune system. These have been shown to elevated Th1 T cell responses in mice with 
colitis, and to thus be dominant antigens which may trigger the immune response in 
genetically susceptible individuals, leading to IBD (Lodes et al., 2004). 
Potential therapeutic benefits include such molecules as superoxide dismutase 1 (SOD1), 
which has been shown to ameliorate colonic inflammatory changes in experimental colitis. 
Down-regulation of adhesion molecule expression, reduction of lipid hydroperoxidation, 
and recruitment of leukocytes into the inflamed intestine contribute to this beneficial effect 
(Segui et al., 2005). Our own studies have demonstrated the potential beneficial effects of 
dietary compounds such as polyunsaturated fatty acids (Knoch et al., 2009; Knoch et al., 
2010) and polyphenols (Nones et al., 2009) on intestinal inflammation. A greater 
understanding of cell to cell adhesion has led to the development of monoclonal antibodies 
against ǂ4 and ǂ4ǃ7 integrins that have been shown to have clinical efficacy (Lanzarotto et 
al., 2006), although there has been some debate as to the safety and efficacy of this approach 
(Davenport and Munday, 2007). 
4. Relevance to the clinic 
We will conclude our chapter by considering how information derived from these models 
has been applied to human IBD, and understanding both the value and limits of the lessons 
that have been learned from animal models. Finally, we will discuss the potential role of 
these models in the future of IBD research, and whether there are other alternatives to assist 
in translating fundamental research into a clinical setting. 
4.1 Limits of animal models of IBD 
Animal models can be an important tool in understanding complex diseases such as UC and 
CD, but it is important to remember that they are simply models. As such, they by definition 
will have some limitations, and while there are many similarities between experimental 
ulcerative disease of of the colon and human IBD, there are also differences. These can be 
either morphological (e.g., initial site of involvement of the bowel) or clinical. An example of 
a clinical difference is that spontaneous remission is sometimes seen in human disease 
(particularly with UC) but this is not seen in chemically-induced models unless exposure to 
the chemical is ceased. Mice may not be truly representative of other mammalian systems as 
has been observed with respect to early development (Berg, D. K. et al., 2011), and the 
inherent differences between mice and humans must be borne in mind when using such 
models. 
The relevance of chemically-induced models has been called into question. It was noted 
early in the development of these models that there was a lack of any evidence that human 
ulcerative colitis is produced by the ingestion of compounds related to carrageenan, the 
chemical used to induce colitis (Watt and Marcus, 1973). Such evidence is still lacking, and it 
has also been observed that the acetic acid and TNBS models may have significant 
limitations in understanding events that initiate inflammation of the intestine in human IBD 
(Yamada et al., 1992). More recently, the relevance of the DSS-induced model has also been 
questioned (Petersen et al., 2009). To balance this, it should be noted that ulcerative disease 
of the colon can be caused by ingestion of certain chemical compounds in at least four 
different animal species, which suggests that this mechanism should not be completely 
disregarded with respect to human disease. 
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4.2 Application in a clinical setting 
While animal models have clearly contributed to our knowledge of IBD, particularly in 
terms of understanding disease pathogenesis, the presence of useful progress in terms of 
treatment is less clear. There is an apparent lack of integration of mouse model data into the 
clinical setting, a so-called “missing link” between models and clinic (Petersen et al., 
2009). This is seen in the conclusions to many studies incorporating such models, or 
indeed articles reviewing the use of these models, which tend to finish with statements 
referring to future, rather than current, therapeutic advances. Some examples of such 
conclusions are as follows (note that italics are not in the original references): “...promising 
target for the Inflammatory Bowel Diseases (IBD) treatment” (Andrzejak et al., 2011); 
“substantial investment from the pharmaceutical industry should deliver novel therapies 
arising from gene discovery to the clinic within the next 5 years” (Lees et al., 2011); 
“...recently established genetically engineered mouse models lacking IBD susceptibility 
gene should be promising tools to develop novel therapeutic measures for IBD” (Mizoguchi 
and Mizoguchi, 2010).   
This is not to detract from some excellent research in the field, and the recently established 
genetically engineered mouse models lacking IBD susceptibility genes should indeed prove 
to be promising tools to develop novel therapies. For example, based on the numerous 
studies involving the Il10–/– mouse model demonstrating the importance of this anti-
inflammatory cytokine in IBD, several human clinical trials have been carried out using IL-
10. However, these have not shown a clear beneficial effect of IL-10 therapy. This has been 
attributed to polymorphisms of IL-10 receptors hampering effectiveness of this therapy for 
patients, or to the instability and short half-life of IL-10. More promisingly, engineered lactic 
acid bacteria have successfully delivered biologically active IL-10 into the intestine of both 
animal models (Wells and Mercenier, 2008) and some CD patients (Braat et al., 2006) 
indicating a potential bio-therapeutic application for IL-10.  
4.3 Future relevance of animal models of IBD  
It has been observed that differences between animal models may reflect the different 
subgroups of patients with IBD (Jurjus et al., 2004). This may be the case for some models, 
although the chemically-induced models may in fact be less relevant in terms of the clinical 
situation. Nevertheless, it seems clear that some of the genetically-based models may be of 
particular relevance for certain forms of IBD. In future, studies may utilise a specific mouse 
model targeted at the most appropriate subgroups and thus provide more relevant data. 
However, this will in turn rely on establishment of more clearly defined clinical phenotypes 
and the widespread application of genetic tests in clinical medicine to enable accurate 
matching of mouse model to patient thereby leading to the most appropriate therapy. The 
identification of appropriate diagnostic biomarkers would be of particular benefit in this case, 
both in terms of classification and subsequent monitoring of the effectiveness of therapies.  
This potential ‘matching’ of model to patient sub-group may be constrained by financial 
considerations, nonetheless this personalised approach to treatment may be the most 
effective due to the heterogeneity of IBD. Recent evidence showing potential gene-diet 
interactions in IBD (Petermann et al., 2009b) and the potential for diet to modulate IBD 
through anti-inflammatory action or alteration of the microbiota (Issa and Saeian, 2011) 
suggests that dietary intervention appropriately matched to patient genotype may be an 
important aspect of successful therapy.  
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Mouse models will continue to be a pivotal part of IBD research. The complexity of the 
disease cannot currently be adequately modelled by in vitro or in silico approaches and 
requires an in vivo approach. Some novel therapies have shown promising initial data in 
limited human clinical trials, for example administration of viable eggs from the porcine 
whipworm, Trichuris suis, to patients with CD and UC, which may act to down-regulate the 
chronic Th1 immune response (Summers et al., 2003). However, more convincing safety and 
efficacy data derived from animal models are required before further human clinical trials 
using these novel treatments are conducted, particularly as some proposed treatments may 
have adverse effects on normal immune homeostasis (Grimm, 2009). 
It has been observed that IBD may result from inappropriate responses to normal bacteria in 
a genetically susceptible host, which may arise due to some sort of environmental trigger. 
This situation is clearly seen in the Nod22939iC mouse, where the animals do not develop an 
inflammatory phenotype unless challenged with DSS, an insult which appears to damage 
the epithelial barrier and allow bacteria to infiltrate the mucosa, leading to an inappropriate 
response in the Nod22939iC, but not the wild-type, mouse. The requirement for a trigger in the 
form of DSS may make this model more relevant, as it could reflect the situation seen in 
human patients with this gene variant, who may have been exposed to some form of 
intestinal insult (dietary, or an infection) which has enabled the interaction with bacteria to 
occur. However, the fact that DSS is the trigger could be a weakness; as already observed, 
this particular compound has been questioned in terms of its relevance, and it may be that a 
more relevant trigger (e.g. dietary) needs to be found before such a model could be truly 
relevant. 
The current comprehensive knowledge of the potential genetic component of both CD and 
UC, and rapid decreases in the cost of techniques to accurately measure these on an 
individual level, mean that more accurate classification of disease based on both clinical and 
genetic factors is achievable. The presence of multiple animal models, which may reflect 
these more accurately classified subgroups, means that a more targeted use of these models 
can be made. There is a growing body of evidence on the interactions between drugs 
(pharmacogenomics) or foods (nutrigenomics) and an individual’s genotype. A truly 
personalised approach to managing IBD using appropriate preventive or therapeutic 
pharmacological or nutritional interventions is a future prospect if continued advances are 
made in this area.  
In summary, there is clearly still a role for animal models of IBD, however more appropriate 
use of new information and technologies, better classification of IBD based on both 
phenotypic and genetic information, and closer alliances between fundamental biological 
researchers and clinicians are required to ensure that the key lessons from these models are 
effectively moved into clinical practice. This should enable more successful strategies for the 
prevention and amelioration of this debilitating condition. 
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